Is AOD-9604 Legal in Michigan?

What AOD-9604 Is and Why Legality Is Complicated

AOD-9604 is a synthetic peptide fragment derived from amino acids 176 to 191 of human growth hormone. Researchers originally designed it to capture the lipolytic (fat-burning) properties of growth hormone while avoiding the insulin-resistance and growth-promoting effects tied to the full molecule. It is not a controlled substance under the Controlled Substances Act, and it has never been approved by the FDA as a finished pharmaceutical product for any indication. [1]

Because AOD-9604 is neither a scheduled drug nor an approved drug, it falls into a regulatory space that most patients find genuinely confusing. The two most relevant federal mechanisms are (1) the FDA's bulk drug substances program for compounding pharmacies and (2) the broader question of whether unapproved peptides constitute "new drugs" under 21 U.S.C. § 321(p).

The "New Drug" Problem

Under 21 U.S.C. § 321(p), any article intended to affect the structure or function of the human body may qualify as a drug, and any drug not previously approved requires FDA approval before commercial distribution. [2] AOD-9604 has never cleared that bar. Metabolic Pharmaceuticals conducted Phase II trials in the early 2000s and reported statistically significant reductions in body fat compared with placebo, but the program stopped before Phase III enrollment. Without an approved New Drug Application (NDA), AOD-9604 cannot legally be marketed as a finished drug in the United States.

Why Compounding Was the Primary Access Route

For roughly a decade before 2023, many 503A compounding pharmacies (the smaller, patient-specific pharmacies licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act) prepared AOD-9604 injections in response to individual prescriptions. Section 503A allows compounding of bulk drug substances that appear on an FDA-nominated list, commonly called the "bulk substances list" or the 503A bulks list. [3] AOD-9604 appeared on that list in Category 2 (substances under evaluation) for several years, which created a permissive gray zone.

The 2023 FDA Rulemaking That Changed Everything

In November 2023, the FDA finalized its decision to move AOD-9604 off the Category 2 evaluation list without placing it in Category 1 (substances that may be compounded). Practically, this means 503A pharmacies no longer have a regulatory pathway to compound AOD-9604 for individual patient prescriptions. [4]

The agency's reasoning centered on two points. First, there was no published clinical evidence meeting FDA's evidentiary standard for safety and effectiveness sufficient to support compounding. Second, the peptide had been studied as a potential new drug by a named sponsor, which ordinarily disqualifies a substance from the bulk-compounding pathway.

What 503B Outsourcing Facilities Can Do

Section 503B outsourcing facilities operate under different rules than 503A pharmacies. They can compound drug products without patient-specific prescriptions, but they are limited to drugs that appear on FDA's 503B bulks list or that are essentially copies of FDA-approved drugs. AOD-9604 does not appear on the 503B bulks list, so outsourcing facilities face the same barrier. [3]

FDA Warning Letters: A Pattern Worth Noting

The FDA issued multiple warning letters to peptide-compounding pharmacies between 2020 and 2024, specifically citing unapproved bulk peptides including BPC-157, TB-500, and related compounds. While not every letter named AOD-9604 directly, the agency's enforcement posture makes clear that unapproved peptide compounding is an active priority. [5] Practitioners and patients who rely on compounded AOD-9604 sourced after November 2023 should understand that both the pharmacy and potentially the prescribing clinician face regulatory scrutiny.

Michigan State Law: What the Board of Pharmacy Actually Governs

Michigan has no statute that either explicitly bans or explicitly authorizes AOD-9604. The Michigan Public Health Code (MCL 333.17701 through 333.17780) governs pharmacy practice in the state, and it incorporates federal standards for drug approval by reference rather than carving out state-specific peptide rules. [6] That means the federal determination described above flows directly into Michigan practice.

Michigan Board of Pharmacy Compounding Rules

Michigan-licensed 503A pharmacies must comply with USP Chapter 797 for sterile compounding and must use bulk drug substances that are either (a) components of FDA-approved drugs, (b) on the FDA 503A bulk list, or (c) supported by a peer-reviewed monograph published in a recognized pharmacy compendium. [6] AOD-9604 meets none of these criteria as of 2025.

The Michigan Board of Pharmacy has not issued a separate advisory opinion on AOD-9604, but its rules make clear that compounding a substance outside the permitted pathways constitutes a violation of the Pharmacy Practice Act. A pharmacist who prepares AOD-9604 under a Michigan license today risks disciplinary action ranging from a formal reprimand to license suspension.

Michigan Medical Practice Act and Prescriber Liability

Michigan physicians operate under the Michigan Medical Practice Act (MCL 333.17001 et seq.) and are subject to the Michigan Board of Medicine. [7] A physician may legally write a prescription for a compound that a pharmacy is authorized to prepare. The problem is the pharmacy authorization, not the prescription itself.

Prescribing a compound that no legally operating pharmacy can fill does not make the prescription illegal per se, but it creates practical dead ends and raises standard-of-care questions. The Michigan Board of Medicine has not published specific guidance on peptide prescribing, but the board routinely considers whether a treatment has "accepted medical use" when evaluating disciplinary complaints. For AOD-9604 in 2025, that standard is difficult to meet given the absence of Phase III data and FDA approval.

The HealthRX clinical team uses a three-gate framework when evaluating any compounded peptide for Michigan patients: Gate 1 checks federal bulk-list status, Gate 2 checks whether a Michigan-licensed pharmacy can legally fill the compound, and Gate 3 assesses whether published clinical evidence supports the proposed indication. AOD-9604 currently fails Gate 1 and Gate 2, which means Gate 3 evaluation is moot for clinical dispensing purposes, regardless of how promising early trial data appeared.

Clinical Evidence: What the Trials Actually Found

The Phase II data on AOD-9604 come primarily from trials conducted by Metabolic Pharmaceuticals in Australia. A 12-week, double-blind, placebo-controlled study (N=300) published in 2001 reported that AOD-9604 at 1 mg/day oral formulation produced a statistically significant reduction in body fat compared with placebo (P<0.05), though the absolute weight-loss magnitude was modest. [8] A later injectable formulation study reported similar directional results.

These trials were adequate to justify further investigation but were not powered or designed to support an NDA. The FDA's 2023 decision implicitly acknowledged this evidence gap. For context, the semaglutide STEP-1 trial (N=1,961) showed 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo, giving regulators a high evidentiary bar for any new obesity treatment. [9]

Safety Data: What Is and Is Not Known

No serious adverse events directly attributed to AOD-9604 were reported in the Phase II trials, and the peptide did not stimulate IGF-1 levels at therapeutic doses, which is the main safety concern with full-length growth hormone. [8] However, the long-term safety profile in humans remains unstudied. Phase II trials lasting 12 weeks cannot detect adverse events that manifest over years, and no post-market surveillance exists because the drug never reached approval.

The FDA's guidance on compounded drug products states that "a lack of identified safety concerns in short-term studies does not establish safety for long-term use." [4] That principle applies directly to AOD-9604.

Comparison With Approved Alternatives

Patients seeking weight-management support in Michigan have access to several FDA-approved options. Semaglutide (Wegovy, 2.4 mg weekly subcutaneous) and tirzepatide (Zepbound, up to 15 mg weekly subcutaneous) both carry NDA approval and have multi-year safety datasets from large Phase III programs. [9] Liraglutide (Saxenda, 3 mg daily subcutaneous) and orlistat (Xenical, 120 mg three times daily) provide additional approved options at lower cost. AOD-9604 cannot offer the regulatory transparency or the safety track record of any of these drugs.

How to Legally Discuss or Pursue AOD-9604 in Michigan

Telehealth consultations with a Michigan-licensed physician about AOD-9604 are legal. The consultation itself is not a regulated drug product. The clinician can explain the evidence base, describe the regulatory barriers, and discuss what the compound was originally designed to do. [7] What that clinician cannot ethically or legally do is write a prescription that routes a patient toward a pharmacy operating outside federal compounding law.

Research Chemical Suppliers: A High-Risk Path

Some patients attempt to obtain AOD-9604 from vendors who market it as a "research chemical" not intended for human use. These products are typically sold in powder or lyophilized vial form without sterility testing, potency verification, or pharmaceutical-grade manufacturing standards. The FDA considers human use of research chemicals a violation of federal law when the substance constitutes an unapproved new drug under 21 U.S.C. § 321(p). [2] Michigan law does not create a safe harbor for this route.

Beyond the legal risk, quality-control data from independent testing of peptide "research" products are concerning. A 2023 analysis published in a peer-reviewed journal found that 25 of 26 commercially available peptide samples tested at concentrations or purity levels inconsistent with the label claim. [10] Patients self-injecting from these sources face unknown concentrations of unknown compounds.

What a Legitimate Prescription Pathway Would Require

For AOD-9604 to become legally accessible through compounding in Michigan again, at least one of these three things would need to happen: the FDA would need to add it to the Category 1 (approved) 503A bulk list after reviewing sufficient safety and efficacy data, a pharmaceutical sponsor would need to complete Phase III trials and file a successful NDA, or the FDA would need to issue a formal enforcement discretion policy covering this compound specifically. None of these pathways appears imminent based on publicly available FDA dockets as of mid-2025.

Telehealth and the Michigan Prescriber Relationship

Michigan participates in the Interstate Medical Licensure Compact, which allows physicians licensed in other states to obtain expedited Michigan licensure. [7] Telehealth platforms operating in Michigan must still route prescriptions through Michigan-licensed pharmacies or pharmacies licensed to ship into Michigan. The dispensing constraint is the same regardless of whether the prescriber is physically in Michigan or practicing via telemedicine.

The Endocrine Society's clinical practice guidelines for obesity pharmacotherapy do not list AOD-9604 as a recommended or investigational agent, noting instead that "pharmacological therapy should use agents with demonstrated efficacy and an acceptable safety profile in randomized controlled trials." [11] That language functionally excludes AOD-9604 from guideline-supported prescribing.

What Michigan Patients Should Ask Their Provider

Patients curious about peptide therapy for weight management should ask their provider three specific questions. First, is the compound on the current FDA 503A or 503B bulk list? Second, can the provider identify a Michigan-licensed pharmacy that will legally fill the prescription? Third, what is the Phase III evidence base, and how does it compare with FDA-approved alternatives?

If a provider cannot answer the first two questions affirmatively, the patient is likely being steered toward a pathway that carries regulatory and safety risk. A provider who answers those questions honestly will typically redirect toward semaglutide, tirzepatide, or another approved agent, and document the informed-consent discussion accordingly.

Enforcement Field: What Has Actually Happened to Providers

The FDA's Office of Criminal Investigations has pursued criminal charges against compounding pharmacy operators for distributing unapproved drugs, including peptides. In several documented enforcement actions between 2019 and 2024, pharmacists and clinic operators faced charges under the FDCA's misbranding and adulteration provisions. [5] No Michigan-specific enforcement action involving AOD-9604 has been publicly identified, but the absence of a Michigan case does not mean Michigan is a safe jurisdiction.

The Federal Trade Commission has also issued warning letters to online vendors making weight-loss claims for unapproved compounds, and the FTC's enforcement priorities for 2024 and 2025 explicitly include peptide marketing. Patients who see AOD-9604 advertised for weight loss online are looking at marketing that may itself be in violation of FTC regulations.